# **BLISS GVS PHARMA LTD.**



## August 03, 2022

То	То
The Manager, Listing Department	The General Manager, Listing Department
National Stock Exchange of India Ltd.	BSE Limited
Plot no. C/1 G Block,	Phiroze Jeejeebhoy Towers,
Bandra-Kurla Complex, Bandra (East),	Dalal Street,
Mumbai- 400 051	Mumbai- 400 001
Symbol: BLISSGVS	Scrip Code: 506197

# Subject: Outcome of Board Meeting held on Wednesday, August 03, 2022

Dear Sir/Madam,

We would like to inform you that, Board Meeting of the Company was held today i.e. Wednesday, August 03, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others:

1. The Unaudited Standalone and Consolidated Financial Results of the company for the quarter ended June 30, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.

The meeting of the Board of Directors commenced at 04:30 p.m. and concluded at 08:30 p.m.

Kindly take the above information on your record and acknowledge

Thanking you.

Yours Faithfully,

For Buss GVS Pharma Limited



Encl: As above

 Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

 TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

 Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

 Factory :
 Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

 Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com



#### BLISS GVS PHARMA LIMITED Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072 Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2022

					or the quarter	ended June 30,	LULL	5	(₹ in Lakh)
		Standalone			Consolidated				
Sr. No	Particulars	Quarter Ended			Year Ended		Quarter Ended		Year Ended
51.140	Faiticulars	June 30, 2022	Mar 31, 2022	June 30, 2021	Mar 31, 2022	June 30, 2022	Mar 31, 2022	June 30, 2021	Mar 31, 2022
		Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited
1	Revenue from Operations	14,727.97	13,830.14	13,303.05	63,635.67	18,866.16	16,706.34	16,814.54	74,745.41
п	Other Income	1,863.37	1,243.57	789.54	3,262.79	701.09	1,218.84	781.72	3,149.19
ш	Total Income (I+II)	16,591.34	15,073.71	14,092.59	66,898.46	19,567.25	17,925.18	17,596.26	77,894.60
IV	Evenence			3 A.	1 × 1		. L. P.	- F	
a.	Expenses Cost of Materials consumed	7,325.71	7,793.17	7,228.50	35,083.08	8,058.35	8,925.92	8,312.65	38,526.98
a. b.	Purchase of Stock-in-Trade	7,525.71	(9.04)	215.78	200.80	1,386.68	440.80	1,384.46	3,491.33
с.	Changes in inventories of work in process, finished goods	920.15	(291.31)	(610.10)	(889.60)	72.45	(664.85)	(1,021.11)	(2,920.11)
	and stock in trade		,,	(/	(,		(		(_,,
	Patrice in The Contraction and						and a strate line		
d.	Employee Benefits Expense	1,739.14	1,704.85	1,538.22	6,505.59	2,055.21	2,019.01	1,773.97	7,614.82
e.	Finance Costs	204.18	153.72	130.05	432.44	211.35	163.07	139.86	474.21
с.								200100	
f.	Depreciation and Amortisation Expense	367.42	340.61	348.13	1,384.73	455.01	426.93	433.41	1,733.08
	Other Expenses	2,828.15	2,764.43	2,337.58	11,815.90	3,408.35	3,968.88	2,904.43	16,198.31
g.	Other Expenses	2,020.13	2,704.45	2,557.56	11,015.50	5,400.55	5,508.88	2,504.45	10,190.51
	Total Expenses	13,384.75	12,456.43	11,188.16	54,532.94	15,647.40	15,279.76	13,927.67	65,118.62
v	Profit before exceptional Items and tax	3 306 50	2 617 20	2,904.43	12,365.52	3,919.85	2,645.42	2 669 60	12 775 00
v	(III-IV)	3,206.59	2,617.28	2,904.45	12,505.52	5,919.65	2,045.42	3,668.59	12,775.98
VI	Exceptional Items				274.51		-		(7,359.45)
vi.	Exceptional items	-		-	2/4.51	-	-	-	(7,555.45)
VII	Profit before Tax (V-VI)	3,206.59	2,617.28	2,904.43	12,640.03	3,919.85	2,645.42	3,668.59	5,416.53
						9			
VIII	Tax Expense	004 50	554.00	640.07	2 402 22	4 030 50	642.05	055.00	0.040.57
	i.Current Tax	864.59	564.09	640.07	3,192.33	1,039.50	643.85	955.29	3,913.57
	ii.Deferred Tax Liability/(Asset)	(122.52)	142.71	98.56	76.77	131.82	95.96	98.79	(474.31)
	iii. Short/ Excess Provision of earlier years		-	•	104.53	0.56	(441.08)	1.37	(335.38)
IX	Net Profit for the period	2,464.52	1,910.48	2,165.80	9,266.40	2,747.97	2,346.69	2,613.14	2,312.65
				a					
х	Other Comprehensive Income								
	i. Items that will not be reclassified to profit or loss	32.62	23.81	14.94	40.45	32.62	23.81	14.04	40.45
	(i) Remeasurement of the defined benefit liabilities/ (asset)			(3.76)			(5.99)	14.94	
	<ul> <li>(ii) Income tax on remeasurement of defined benefits liabilities/ (assets)</li> </ul>	(8.21)	(5.99)	(5.76)	(10.18)	(8.21)	(5.99)	(3.76)	(10.18)
	habilities/ (assets)								×
	ii. Items that will be reclassified to profit or loss								
	(i) Exchange differences in translating the financial	-	-	-	· •	(275.38)	(827.16)	(110.23)	(1,030.51)
	statements of foreign operations								
	(ii) Income tax relating to items that will be reclassified to	-		-	-	76.46	45.21	27.74	259.38
	profit or loss								
хі	Total Comprehensive Income for the period	2,488.93	1,928.30	2,176.98	9,296.67	2,573.46	1,582.56	2,541.83	1,571.79
XII	Profit attributable to :							100 X X X	
	i. Owners of the Company	-	-	-	-	2,571.93	1,963.20	2,425.42	1,504.02
	ii. Non-controlling interests	-	-	-	-	176.04	383.49	187.72	808.63
XIII	Other Comprehensive Income attributable to :							1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	
	i. Owners of the Company	-			-	(188.41)	(765.40)	(73.63)	(740.86)
	il. Non-controlling interests			-	-	13.90	1.27	2.32	-
XIV	Total Comprehensive income attributable to :							2	10-00-00
	i. Owners of the Company	-	-	-	-	2,383.52	1,197.80	2,351.79	763.16
	ii. Non-controlling interests	-	-	-		189.94	384.76	190.04	808.63
xv	Paid up equity share capital	1,038.08	1,036.78	1,033.57	1,036.78	1,038.08	1,036.78	1,033.57	1,036.78
	(Face Value - ₹ 1/- each)	2,000.00	2,000.70	2,000.07	2,000.70	2,000.00	2,000.70	2,033.57	2,030.70
х	Earnings Per Share Basic & Diluted (Not Annualised) (₹)								
	1. Basic	2.38	1.85	2.10	8.97	2.48	1.90	2.35	1.46
	ii. Diluted	2.34	1.82	2.04	8.81	2.44	1.87	2.29	1.43








#### Notes :

- 1 The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 3, 2022. These unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules in this regard.
- 2 The current quarter results have been subject to a limited review by the statutory auditors of the Company. The statutory auditors, Kalyaniwalla & Mistry LLP have issued limited review reports with unmodified conclusion on the standalone and consolidated financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of ₹ 104.06 Lakh (Previous Period ₹ 148.16 Lakh) as per Ind AS 102 for the quarter ended June 30, 2022.
- 5 During the quarter ended June 30, 2022, the Company has allotted 1,30,250 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP scheme, 2019. From the total 40,57,000 number of options granted, the outstanding number of options as at June 30, 2022 are 17,83,000.
- 6 Figures for previous periods have been regrouped/ reclassified wherever necessary.
- 7 The figures for the quarter ended March 31,2022 are the balancing figures between audited figures for the full financial year and the published year to date figures upto nine months ended December 31,2021.



For BLISS GVS MITED NUMB gan Harsh Sharma Managing Director Din No: 07939421

# KALYANIWALLA & MISTRY LLP

# CHARTERED ACCOUNTANTS

To,

The Board of Directors, Bliss GVS Pharma Limited, 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai 400 072.

#### LIMITED REVIEW REPORT

- 1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Bliss GVS Pharma Limited** ('the Company'), for the quarter ended June 30, 2022 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") (initialed by us for identification).
- 2. This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Company's Board of Directors at their respective meetings held on August 03, 2022, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

LLP IN : AAH - 3437

#### 5. Emphasis of Matter:

We draw attention to our reliance on the management representation including cash flow projections in respect of the recoverability of the Company's investment in, loans outstanding, Interest accrued and due thereon and trade receivables from two of its subsidiaries and its two step-down subsidiaries aggregating to Rs. 17,421.01 Lakh.

Our conclusion is not modified in respect of this matter.

### 6. Other Matter:

Attention is drawn to the fact that the figures for the quarter ended March 31, as reported in these standalone financial results are the balancing figures between audited figures in respect of the full financial year ended March 31 and published year to date figures up to the end of the third quarter of the relevant financial year. The figures up to the end of third quarter have only been reviewed by us and not subject to audit.

Our conclusion is not modified in respect of this matter.

For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS Firm Registration No. 104607W/W100166

Sai Venkata Ramana Damarla Partner Membership No. 107017 UDIN: 2210 7017A0EYNT2452 Place: Mumbai Dated: August 03, 2022.

# KALYANIWALLA & MISTRY LLP

#### CHARTERED ACCOUNTANTS

To, The Board of Directors, Bliss GVS Pharma Limited, 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai -400 072.

#### LIMITED REVIEW REPORT

- We have reviewed the accompanying Statement of unaudited consolidated financial results of Bliss GVS Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2022 ("the Statement"),attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") (initialed by us for identification).
- 2. This Statement, which is the responsibility of the Parent's Management has been reviewed by the Audit Committee and approved by the Parent's Board of Directors at their respective meetings held on August 03, 2022, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

#### A. Incorporated in India:

1. Kremoint Pharma Private Limited, India 1.1. Eipii Exports Private Limited, India (subsidiary of 1. above)

#### LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001 TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

#### **B.** Incorporated outside India:

2. Bliss GVS International Pte. Ltd., Singapore

2.1. Greenlife Bliss Healthcare Limited, Nigeria (subsidiary of 2. above)

2.2. Asterisk Lifesciences DRC, Democratic Republic of Congo. (subsidiary of 2. above)

3. Asterisk Lifesciences Limited (UK), United Kingdom

3.1. Asterisk Lifesciences (GH) Limited, Ghana (subsidiary of 3. above)

5. Based on our review procedures conducted as mentioned above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## 6. Other Matters:

a. We did not review the interim financial information of 6 subsidiaries included in the Statement, whose financial results reflect the Group's share for the quarter ended June 30, 2022, for the under mentioned items (before consolidation adjustments). These interim financial statements and other financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management, and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent, they have been derived from such financial statements is based on the report of such other auditors.

5.	(In Lakh)
Particulars	Quarter Ended June 30, 2022
Total Revenue	5,626.38
Loss After Tax	(466.55)
Total Comprehensive Income	(438.16)

b. We did not review the interim financial information of a subsidiary, i.e., Asterisk Lifesciences DRC, Democratic Republic of Congo, included in the Statement, whose financial results reflect the Group's share for the quarter ended June 30, 2022 for the under mentioned items (before consolidation adjustments). These interim financial statements and other financial information has been certified and furnished to us by the Parent's Management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent, they have been derived from such management certified financial statements. According to the information and explanations given to us by the Parent's Management, these financial results are not material to the Group.

	(In Lakh)
Particulars	Quarter Ended June 30, 2022
Total Revenue	- ·
Loss After Tax	(3.60)
Total Comprehensive Income	(3.60)

c. Attention is drawn to the fact that the figures for the quarter ended March 31, as reported in these consolidated financial results are the balancing figures between audited figures in respect of the full financial year ended March 31 and published year to date figures up to the end of the third quarter of the relevant financial year. The figures up to the end of the third quarter have only been reviewed by us and not subject to audit.

Our conclusion on the Statement is not modified in respect of the above matters.

For KALYANIWALLA AND MISTRY LLP CHARTERED ACCOUNTANTS Firm Registration No. 104607W/W100166

8. Seri

Sai Venkata Ramana Damarla Partner Membership No. 107017 UDIN: 22107017A0EYQI7330 Place: Mumbai, Dated: August 03, 2022.